Clinical Trial

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
Business decision to move away from this indication with this intervention, and low enrollment.
Summary
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-09-08; most recent amendment 2026-02-23.
Status change: Recruiting → Withdrawn 2026-02-23
Status change: Not Yet Recruiting → Recruiting 2025-12-16
Trial Details
NCT Number NCT07172867
Lead Sponsor Halia Therapeutics, Inc.
Conditions Diabetes Mellitus, Type 2, Obesity
Start Date 2026-01-06
Primary Completion 2026-01-23 (estimated)
Study Completion 2026-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-02-25